金凯（辽宁）生命科技股份有限公司 已审财务报表 2024年度 金凯（辽宁）生命科技股份有限公司 目 录 | | 页 次 | | | --- | --- | --- | | 审计报告 | 1 - | 6 | | 已审财务报表 | | | | 合并资产负债表 | 7 - | 8 | | 合并利润表 | 9 - | 10 | | 合并股东权益变动表 | 11 - | 12 | | 合并现金流量表 | 13 - | 14 | | 公司资产负债表 | 15 - | 16 | | 公司利润表 | 17 | | | 公司股东权益变动表 | 18 - | 19 | | 公司现金流量表 | 20 - | 21 | | 财务报表附注 | 22 - | 90 | | 补充资料 | | | | 非经常性损益明细表 1. | 1 | | | 2. 净资产收益率和每股收益 | 1 | | 审计报告 安永华明（2025）审字第70020911_A01号 金凯（辽宁）生命科技股份有限公司 金凯（辽宁）生命科技股份有限公司全体股东： 一、审计意见 我们审计了金凯（辽宁）生命科技股份有限公司的财务报表，包括2024年12月31 日的合并及公司资 ...

（一）募集资金到位情况 经中国证券监督管理委员会于 2023 年 5 月 18 日《关于同意金凯（辽宁）生 命科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1115 号） 同意注册，金凯生科首次向社会公开发行人民币普通股（A 股）21,508,335.00 股， 发行价格为 56.56 元/股，本次发行募集资金总额为人民币 1,216,511,427.60 元， 扣除相关发行费用后，存放于募集资金专户的募集资金净额为人民币 1,110,744,306.58 元。上述募集资金到位情况已经安永华明会计师事务所（特殊 普通合伙）进行审验，并于 2023 年 7 月 28 日出具了安永华明（2023）验字第 61232239_A01 号《验资报告》。公司依照相关规定对募集资金进行了专户存储管 理，并与本保荐机构、募集资金专户监管银行签署了募集资金专户存储监管协议。 （二）2024 年度募集资金使用及结余情况 中信建投证券股份有限公司关于金凯（辽宁）生命科技股份有限 公司2024年度募集资金存放与使用情况的专项核查报告 中信建投证券股份有限公司（以下简称"中信建投证券"或"本保荐机构"） 作为金凯（ ...

经核查独立董事刘媛媛女士、游松先生、郭玉坤先生的任职经历以及签署的相关 自查文件，上述人员未在公司担任除独立董事以外的任何职务，其配偶、父母、子女、 主要社会关系也未在公司任职，也未在公司主要股东公司担任任何职务，与公司以及 主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系。因此，公 司独立董事符合《 上市公司独立董事管理办法》 深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》中对独立董事独立性的相关要求。 金凯（辽宁）生命科技股份有限公司 董事会 2025 年 4 月 23 日 金凯（辽宁）生命科技股份有限公司 董事会关于 2024 年度独立董事独立性自查情况的专项意见 根据《 中华人民共和国公司法》 上市公司独立董事管理办法》 深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规和规范性 文件及《 金凯《（辽宁）生命科技股份有限公司章程》 金凯《（辽宁）生命科技股份有 限公司独立董事工作规则》的相关规定，金凯《（辽宁）生命科技股份有限公司《（以下 简称"公司"）就 2024 年度在任独立董事刘媛媛女士、游松先生、郭玉坤先生提交 的 ...

金凯（辽宁）生命科技股份有限公司 （一）出席董事会、股东会情况 1、会议出席情况 2024年，公司共召开了5次董事会，4次股东会。 2024年度独立董事述职报告 各位股东及股东代表： 本人作为金凯（辽宁）生命科技股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》《上市公司治理准则》《上市公司独立董 事管理办法》等法律法规以及《金凯（辽宁）生命科技股份有限公司章程》的相关 规定，积极履行职责，恪尽职守，依法履行独立董事应尽的职责，从客观、公正立 场出发，做出独立判断。现将本人2024年度的履职情况报告如下： 一、独立董事的基本情况 本人游松，1963年出生，中国国籍，无境外居留权，研究生学历，博士学位， 教授。1985年7月至今历任沈阳药科大学助教、讲师、副教授。现任沈阳药科大学 教授、三生国健药业(上海)股份有限公司独立董事、公司独立董事。 本人未在公司担任除独立董事以外的其他任何职务，没有为公司提供财务、法 律、管理咨询、技术咨询等服务，本人的配偶、父母、子女、主要社会关系也未在 公司任职，也未在公司主要股东公司担任任何职务，没有从公司及其主要股东或有 利害关系的机构和人员取得额 ...

金凯（辽宁）生命科技股份有限公司 2024年度独立董事述职报告 各位股东及股东代表： 本人作为金凯（辽宁）生命科技股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》《上市公司治理准则》《上市公司独立董 事管理办法》等法律法规以及《金凯（辽宁）生命科技股份有限公司章程》的相关 规定，恪尽职守，从客观、公正立场出发，做出独立判断,依法履行独立董事应尽 的职责。现将本人2024年度的履职情况报告如下： 一、独立董事的基本情况 本人郭玉坤，1974年出生，中国国籍，无境外居留权，研究生学历，博士学位， 副教授。2000年7月至今历任大连理工大学人文学部法律系教师、副教授，北京昂 道律师事务所大连分所兼职律师，现任北京融商（大连）律师事务所兼职律师、大 连理工大学人文学部法律系副教授，大连市仲裁委员会仲裁员、公司独立董事。 本人未在公司担任除独立董事以外的其他任何职务，没有为公司提供财务、法 律、管理咨询、技术咨询等服务，本人的配偶、父母、子女、主要社会关系也未在 公司任职，也未在公司主要股东公司担任任何职务，没有从公司及其主要股东或有 利害关系的机构和人员取得额外的未予披露的其他利益，不存 ...

金凯（辽宁）生命科技股份有限公司 2024年度独立董事述职报告 各位股东及股东代表： 本人作为金凯（辽宁）生命科技股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》《上市公司治理准则》《上市公司独立董 事管理办法》等法律法规以及《金凯（辽宁）生命科技股份有限公司章程》的相关 规定，本着恪尽职守、勤勉尽责的工作态度依法履行独立董事应尽的职责。现将 2024年度的履职情况报告如下： 1、会议出席情况 本人刘媛媛，现任东北财经大学会计学院教授，会计学博士。2021年4月起担 任金凯生科独立董事，兼任中铁铁龙集装箱物流股份有限公司、冰山冷热科技股份 有限公司两家境内上市公司独立董事。 本人未在公司担任除独立董事以外的其他任何职务，没有为公司提供财务、法 律、管理咨询、技术咨询等服务，本人的直系亲属、主要社会关系也未在公司任职， 也未在公司主要股东公司担任任何职务，没有从公司及其主要股东或有利害关系的 机构和人员取得额外的未予披露的其他利益，不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席董事会、股东会情况 2024年，公司共召开了5次董事会，4次股东会。 本年度出席历次会议情 ...

Financial Performance - The company experienced a significant decline in performance compared to the same period last year due to factors such as international trade environment and fluctuations in major customer orders [3]. - The company's operating revenue for 2024 was ¥497,010,912.73, a decrease of 35.19% compared to ¥766,824,305.02 in 2023 [22]. - The net profit attributable to shareholders for 2024 was ¥38,609,322.43, down 77.76% from ¥173,574,166.37 in 2023 [22]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥17,362,547.32, a decline of 89.66% from ¥167,843,305.36 in 2023 [22]. - The basic earnings per share for 2024 was ¥0.32, representing an 81.50% decrease from ¥1.73 in 2023 [22]. - The total assets at the end of 2024 were ¥2,263,389,145.02, a decrease of 2.04% from ¥2,310,635,609.21 at the end of 2023 [22]. - The net assets attributable to shareholders at the end of 2024 were ¥2,148,819,290.03, down 1.02% from ¥2,171,004,806.01 at the end of 2023 [22]. - The company reported a net cash flow from operating activities of ¥154,897,880.33, a slight decrease of 0.17% compared to ¥155,156,353.42 in 2023 [22]. Dividend Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of 4.00 RMB per 10 shares (including tax) to all shareholders based on 120,446,669 shares [4]. - The company distributed a total cash dividend of RMB 68.8267 million, accounting for 39.65% of the net profit attributable to shareholders for the year 2023 [118]. - The proposed cash dividend for 2024 is RMB 4.00 per 10 shares, totaling RMB 48.1787 million, which represents 124.79% of the net profit for the year [121]. Market Position and Strategy - The company aims to enhance service capabilities, increase overseas investments, and optimize customer structure to mitigate related risks in the future [3]. - The company is focused on expanding its market presence and developing new products and technologies to drive future growth [4]. - The company is positioned to benefit from the ongoing growth in the global pharmaceutical market and the increasing outsourcing trend in drug development [31]. - The company plans to enhance service capabilities by upgrading laboratory hardware and software, increasing R&D investment, and improving comprehensive service capabilities from laboratory services to API production [77]. - The company will increase investment in its U.S. production base by acquiring land, expanding facilities, and updating equipment to better serve local customers and mitigate trade policy impacts [78]. - The company aims to optimize its customer structure by strengthening its business development team and expanding into the Asia-Europe market to reduce the impact of trade policies and customer fluctuations [78]. Research and Development - The company increased its R&D investment to 7.15% of operating revenue, with a year-on-year increase of 18.29% [44]. - The company is focusing on the development of fluorinated compounds and aims to enhance its market competitiveness through various R&D projects [53][54]. - The company has developed numerous process routes for small molecule compounds, addressing technical bottlenecks and ensuring implementation of R&D routes [36]. - The company provides comprehensive CDMO services, from gram-scale sample process development to kilogram and ton-scale production, enhancing R&D efficiency and reducing costs for clients [35]. Environmental Compliance - The company complies with multiple environmental protection laws and regulations, including the Clean Water Act and Clean Air Act [128]. - The company invested CNY 41.4954 million in environmental protection during the reporting period and paid CNY 5,600 in environmental protection tax [137]. - The company purchased a total of 14,925,000 kWh of green electricity, resulting in a reduction of 13,013,107.50 kg of CO2 emissions, 7,014.75 kg of SO2, and 6,417.75 kg of nitrogen oxides [137]. - The company has a wastewater treatment capacity of 700 tons per day, utilizing a multi-step treatment process to ensure compliance with discharge standards [132]. - The company received the provincial-level green factory title from the Liaoning Provincial Department of Industry and Information Technology in September 2023 [132]. Governance and Management - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments, urging investors to remain aware of investment risks [3]. - The company has established a governance structure that includes a board of directors, supervisory board, and shareholder meetings, all operating independently from controlling shareholders [88]. - The company has implemented a performance-based remuneration system for its employees [104]. - The total remuneration for directors, supervisors, and senior management in 2024 is 11.3146 million yuan [104]. - The company has a structured remuneration decision process involving the board and shareholders [104]. Risks and Challenges - The company faces risks related to changes in international trade policies, which may impact its overseas business operations [76]. - The company faces risks from fluctuations in terminal demand due to operational pressures on global pharmaceutical companies and financing challenges for small innovative drug firms, which could impact revenue significantly [77]. - The investment progress of the company has been slow due to changes in international trade policies and fluctuations in new drug terminal demand [71]. Shareholder Relations - The company held its first temporary shareholders' meeting in January 2024 with a participation rate of 59.35% [91]. - The company’s annual shareholders' meeting in April 2024 had a participation rate of 59.29% [91]. - The second temporary shareholders' meeting in September 2024 had a participation rate of 58.68% [91]. - The company has ensured that all remuneration payments were made in full according to the established standards [104]. Financial Management - The company has a total of 120,446,669 shares after the capital reserve conversion, with a 40% increase from the previous total [194]. - The company has entrusted financial management with a total of 133,457.22 million CNY, with no overdue amounts [188]. - The company has a total of 711 employees, with 451 in production, 155 in technical roles, and 14 in sales [115]. Compliance and Legal Matters - The company has not faced any penalties or rectification issues during the reporting period [174]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant debts due [175]. - The company reported no related party transactions during the reporting period [176].

二、前10名无限售条件股东持股情况 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.3900 | 0.1900 | 105.26 | 0.6300 | | 每股净资产（元） | 18.24 | 25.45 | -28.33 | 14.24 | | 每股公积金(元) | 13.25 | 18.88 | -29.82 | 8.21 | | 每股未分配利润(元) | 3.47 | 4.92 | -29.47 | 4.50 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.76 | 1.24 | 41.94 | 2.14 | | 净利润(亿元) | 0.47 | 0.17 | 176.47 | 0.41 | | 净资产收益率(%) | 2.18 | 0.77 | 183.12 | 4.52 | | 名称 | 持有数量(万股) | 占总股本比 | 增减情 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥176,343,757.34, representing a 41.83% increase compared to ¥124,332,621.75 in the same period last year[4] - Net profit attributable to shareholders was ¥47,417,837.41, a significant increase of 183.24% from ¥16,741,205.71 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥42,553,380.50, up 171.28% from ¥15,686,119.75 in the previous year[4] - The basic and diluted earnings per share both increased by 105.26% to ¥0.39 from ¥0.19[4] - Total operating revenue for the current period reached ¥176,343,757.34, a 42% increase from ¥124,332,621.75 in the previous period[20] - Net profit for the current period was ¥47,417,837.41, compared to ¥16,741,205.71 in the previous period, representing a 183% increase[21] - Basic and diluted earnings per share increased to ¥0.39 from ¥0.19, marking a 105% rise[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,313,499,980.56, a 2.21% increase from ¥2,263,389,145.02 at the end of the previous year[4] - Current assets totaled RMB 1,579,764,504.34, up from RMB 1,503,877,958.89, indicating an increase of about 5.5%[17] - Total liabilities stood at RMB 116,704,446.63, slightly up from RMB 114,569,854.99, showing a marginal increase of about 1.9%[18] - The total equity attributable to the parent company reached RMB 2,196,795,533.93, compared to RMB 2,148,819,290.03 at the beginning of the period, reflecting an increase of approximately 2.2%[19] Cash Flow - The company's cash flow from operating activities decreased by 37.98% to ¥46,227,892.04 from ¥74,538,568.94 in the same period last year[4] - Operating cash flow net amount was ¥46,227,892.04, down from ¥74,538,568.94 in the previous period, indicating a decrease of 38%[23] - Cash and cash equivalents at the end of the period totaled ¥239,990,036.73, down from ¥536,014,618.49, a decline of 55%[23] - Investment activities generated a net cash flow of ¥2,528,001.29, a significant recovery from a net outflow of ¥21,447,108.10 in the previous period[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,778[10] - Kingchem (China) held 48.66% of the shares, making it the largest shareholder[11] - The total number of restricted shares at the end of the period was 63,705,741, with no changes during the reporting period[14] Expenses - Total operating costs amounted to ¥125,403,640.07, up from ¥110,839,890.09, reflecting a 13% increase[20] - The company's inventory decreased to RMB 175,026,165.78 from RMB 194,971,270.02, indicating a decline of about 10.3%[17] - The non-current assets totaled RMB 733,735,476.22, down from RMB 759,511,186.13, representing a decrease of approximately 3.4%[18] - The company's retained earnings increased to RMB 417,881,637.49 from RMB 370,607,655.09, reflecting a growth of about 12.7%[19] - The company reported a decrease in sales expenses to ¥4,899,774.21 from ¥5,094,051.33, a reduction of 4%[20] - Research and development expenses slightly increased to ¥7,018,049.89 from ¥6,964,404.48, reflecting a growth of 1%[20] Investment Income - The company reported a 111.52% increase in investment income to ¥3,377,328.16, compared to ¥1,596,683.03 in the previous year[9] Other Comprehensive Income - Other comprehensive income after tax showed a loss of ¥512,035.25 compared to a gain of ¥264,604.89 in the previous period[21]

CRO概念股盘初下挫，双成药业（002693）跌停，万邦医药（301520）跌超5%，谱尼测试 （300887）、新天地（301277）、金凯生科（301509）跟跌。 ...